
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute is expected to see strong success in the near future due to their promising results in the ongoing upLIFT study and the potential for a positive outcome from the FDA regarding the regulatory pathway for their drug. The company also has a solid pipeline and partnerships to support their development. With a projected 70% PoS for their program in tumor HI, a potential 2035 revenue of $137M, and a projected PT of $11 based on a 10-year DCF analysis, Rezolute shows strong potential for growth and value creation for investors.
Bears say
Rezolute is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases, including congenital hyperinsulinism. However, their success is dependent on regulatory approvals and the commercialization of their drug candidates. There is potential for competition in the market as well as the need for additional funding, which presents balance sheet risk and could impact the company's profitability.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares